Product Images Clopidogrel Bisulfate

This is a comparison of the effectiveness of a placebo with aspirin versus clopidogrel with aspirin in reducing the cumulative event rate of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. The graph shows a significant difference between the two treatments with a p-value of 0.00009.*

This seems to be a statistical table comparing the effects of Clopidogrel and Placebo on different subgroups of participants grouped by their race, previous history of Diabetes, previous history of Stroke, use of Hoparin/LuWH, use of Aspirin level, Beta Blocker usage, and Ace Inhibitor usage. The table shows the number of participants in each subgroup and the percentage that had favorable results with Clopidogrel vs Placebo. The text may have some errors or missing information.*

The text presents the number of deaths and percentages related to two different treatments: placebo and clopidogrel. The placebo treatment had 1845 deaths, which represents 8.1% of the cases. Clopidogrel, on the other hand, had 1726 deaths, which represents 7.5% of the cases. The text also indicates a reduction in the percentage of deaths for both treatments, being statistically significant for the first reduction with a p-value of 0.03. Finally, the days are shown since randomization, up to a maximum of 28 days.*

The text appears to be a chart or table showing the percentage of patients experiencing specific health outcomes, such as death, re-infarction, or stroke, before discharge. The table includes a column labeled "Placebo" and a data point of 10.19 in parentheses next to "even". The chart also includes a column labeled "Days since randomization" with a range of up to 28 days.*

This is a table of medical data, containing information including the number of patients of different genders and ages, their hours since onset, blood pressure, heart rate, and use of fibrinolytic agent. The last section includes percentages of patients who were given Clopidogrel or a Placebo, as well as an Odds Ratio. No further context or explanation is available.*

This is a graph showing the cumulative event rate of fatal or non-fatal vascular events for patients on aspirin versus clopidogrel over a follow-up period of 36 months. The event rate is depicted as a percentage with aspirin having a slightly higher event rate. The graph also shows that at 24 months of follow-up, the difference in event rate between aspirin and clopidogrel is statistically significant (P=0.045).*

This looks like a table showing the results of a study comparing the effectiveness of clopidogrel and aspirin in treating stroke and PAD (peripheral artery disease). The table shows the percentages of patients who qualified for the study, the numbers of patients treated with each drug, and indicates which drug was favored in each group. The final row shows the overall results. The last line shows a measurement of risk (the "hazard ratio") for the two treatments. Without more context or explanation, it's difficult to provide a more detailed description of what this table represents.*

This is a medication package for Clopidogrel bisulfate tablets. Each tablet contains 97.875mg of the medication, manufactured by Graviti Pharmaceuticas Inc. in Delaware, USA. The tablets also contain 75mg of clopidogrel base. The package insert contains information on proper dosages and instructions. The medication should be stored at room temperature, with excursions permitted. Lot-specific information is provided separately to each patient. The package contains 30 tablets and is for prescription use only.*